FIELD: medicine.
SUBSTANCE: method involves introducing effective quantity of imidazole derivative of formula 1.
EFFECT: enhanced effectiveness of treatment.
14 cl, 2 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
IMIDAZOLE DERIVATIVES, METHOD FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF AND METHOD FOR TREATMENT BY THEIR USING | 2001 |
|
RU2265598C2 |
DERIVATIVES OF IMIDAZOLE AND PHARMACEUTICALLY ACCEPTABLE COMPOSITION | 1996 |
|
RU2188194C2 |
IMIDAZOLECARBOXAMIDES AND THEIR USE AS FATTY ACID AMIDE HYDROLASE INHIBITORS | 2014 |
|
RU2671404C2 |
AGENT EFFECTING ON ARTERIAL PRESSURE | 1997 |
|
RU2187309C2 |
ANTIHYPOTENSION MEDICATION | 2007 |
|
RU2353614C1 |
ANESTHETIC COMPOSITION COMPRISING NMDA-ANTAGONIST AND ALPHA-2-ADRENERGIC AGONIST | 2000 |
|
RU2244558C2 |
DEXMEDETOMIDINE SUBLINGUAL COMPOSITIONS AND METHODS OF APPLICATION THEREOF | 2010 |
|
RU2572692C2 |
NON-SEDATIVE A-2-AGONIST 1-(2,3-DIMETHYL-PHENYL)-ETHYL-1,3-DIHYDRO-IMIDASOLE-2-THIONE | 2004 |
|
RU2345987C2 |
PEPTIDE AGONISTS OF VASOPRESSIN RECEPTOR | 2005 |
|
RU2355701C2 |
COMPOUND FOR USE IN TREATING NEUROGENIC ORTHOSTATIC HYPOTENSION | 2017 |
|
RU2723095C1 |
Authors
Dates
2005-09-10—Published
2000-10-27—Filed